Paper Details

  1. Home
  2. Paper Details

Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.

Author: HmweSu Su, IdeTatsuya, InoueTakako, KatoKeizo, KumadaTakashi, ShimadaNoritomo, TakaguchiKoichi, TanakaYasuhito, TorimuraTakuji, ToyodaHidenori, TsubotaAkihito, WakitaTakaji

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluates the efficacy of two hepatitis C virus (HCV) real-time PCR assays, COBAS AmpliPrep/COBAS TaqMan HCV test (CAP/CTM) and Abbott RealTime HCV test (ART), in predicting the clinical outcomes of patients receiving telaprevir (TVR)-based triple therapy or daclatasvir/asunaprevir (DCV/ASV) dual therapy. The study found that CAP/CTM more accurately predicted clinical outcomes in the early phase of TVR-based triple therapy compared to ART. However, ART detected HCV RNA for a longer time, potentially leading to delayed prediction of treatment failure. The study suggests that CAP/CTM may be preferred for predicting clinical outcomes in patients receiving protease inhibitor-based therapy.
Paper Details　
Original Abstract of the Article :
The aim of this study was to determine the efficacy of two hepatitis C virus (HCV) real-time PCR assays, the COBAS AmpliPrep/COBAS TaqMan HCV test (CAP/CTM) and the Abbott RealTime HCV test (ART), for predicting the clinical outcomes of patients infected with HCV who received telaprevir (TVR)-based ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261727/

データ提供：米国国立医学図書館（NLM）

COBAS AmpliPrep/COBAS TaqMan HCV Test: A Reliable Compass for Hepatitis C Treatment

[Hepatitis C virus (HCV)] infection is a serious global health concern. This study, like a camel navigating a treacherous desert landscape, explores the efficacy of two real-time PCR assays in predicting the clinical outcomes of patients receiving [protease inhibitor]-based therapy for HCV infection. The researchers found that the [COBAS AmpliPrep/COBAS TaqMan HCV test (CAP/CTM)] was more accurate than the [Abbott RealTime HCV test (ART)] in predicting treatment response, particularly in the early phases of therapy. This suggests that CAP/CTM might be a valuable tool for guiding treatment decisions and monitoring patient outcomes.

Choosing the Right Compass: A Guide for Hepatitis C Treatment

The study's findings highlight the importance of choosing the right diagnostic tool for monitoring treatment response in patients with HCV infection. CAP/CTM, with its higher accuracy in predicting early treatment response, might be a valuable tool for guiding treatment decisions and ensuring optimal outcomes.

Seeking Help and Staying Informed: A Reminder

If you are concerned about HCV infection or other liver conditions, consult a healthcare professional for diagnosis and treatment options. Remember that early intervention and proper management are crucial for achieving positive outcomes.

Dr.Camel's Conclusion

This study, like a reliable compass in the vast desert of HCV research, sheds light on the importance of choosing the right diagnostic tools for monitoring treatment response. The researchers' findings suggest that CAP/CTM might be a valuable tool for guiding treatment decisions and optimizing patient outcomes. As we continue to explore the desert of HCV research, we may find even more effective tools and therapies for managing this serious condition.

Date :
  1. Date Completed 2017-08-22
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

28118381

DOI: Digital Object Identifier

PMC5261727

Related Literature

Article Analysis
・Effects of telaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.